Systemic use of 5-HT3 receptor antagonists for rheumatic inflammatory processes

摘要

The present invention relates to a new use for compounds having 5-HT3 (serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.